Rosenthal E, Marty P, Poizot-Martin I, Reynes J, Pratlong F, Lafeuillade A, Jaubert D, Boulat O, Dereure J, Gambarelli F
Department of Internal Medicine, University Hospital, Nice, France.
Trans R Soc Trop Med Hyg. 1995 Mar-Apr;89(2):159-62. doi: 10.1016/0035-9203(95)90476-x.
Between 1986 and 1993 visceral leishmaniasis (VL) was diagnosed in 50 adult patients with human immunodeficiency virus type 1 (HIV-1) infection (8 females, 42 males: 31 intravenous drug users, 11 homosexual or bisexual men, 6 heterosexual individuals, 2 blood recipients) from 5 hospital centres in southern France. Diagnosis of VL was by demonstration of Leishmania and isolation of promastigotes by culture in Novy-McNeal-Nicolle medium. Leishmania isolates were identified by their isoenzyme profile in 28 patients. All the patients were immunocompromised when VL was diagnosed. Their median CD4 cell count was 25 x 10(6) (0-200). However, only 21 patients (42%) fulfilled the 1987 CDC criteria for the acquired immune deficiency syndrome before VL developed. Fever (84%), splenomegaly (56%), hepatomegaly (34%), and pancytopenia (62%) were the most common presenting features. Clinical signs were lacking in 10% of patients. Anti-leishmanial antibodies were detected by indirect immunofluorescence or enzyme-linked immunosorbent assay in 26/47 cases (55%). Combining these techniques with Western blotting (WB) gave a positivity rate of 95%. Amastigotes were demonstrated in bone marrow aspirates in 47 cases (94%). Unusual sites for parasites were found in 17 patients (34%), mainly in the digestive tract but also skin and lung. Viscerotropic L. infantum zymodeme MON-1 was characterized in 86% of cases. Dermotropic zymodemes MON-24, MON-29, MON-33, and a previously undescribed zymodeme MON-183, were isolated from 4 patients. The response rate to pentavalent antimony was 50% and to amphotericin B 100%, but clinical relapses were noted in both groups. In endemic areas, VL should be considered as a possible opportunistic infection in HIV-infected patients.(ABSTRACT TRUNCATED AT 250 WORDS)
1986年至1993年间,法国南部5家医院中心诊断出50例患有1型人类免疫缺陷病毒(HIV-1)感染的成年内脏利什曼病(VL)患者(8名女性,42名男性:31名静脉吸毒者,11名同性恋或双性恋男性,6名异性恋者,2名输血者)。VL的诊断通过在诺维-麦克尼尔-尼科尔培养基中培养证明利什曼原虫并分离前鞭毛体来进行。28例患者通过同工酶谱鉴定利什曼原虫分离株。诊断VL时所有患者均免疫功能低下。他们的CD4细胞计数中位数为25×10⁶(0 - 200)。然而,只有21例患者(42%)在VL发生前符合1987年美国疾病控制与预防中心(CDC)的获得性免疫缺陷综合征标准。发热(84%)、脾肿大(56%)、肝肿大(34%)和全血细胞减少(62%)是最常见的临床表现。10%的患者无临床体征。通过间接免疫荧光或酶联免疫吸附试验在26/47例(55%)中检测到抗利什曼原虫抗体。将这些技术与蛋白质印迹法(WB)结合,阳性率为95%。47例(94%)骨髓穿刺物中发现无鞭毛体。17例患者(34%)发现寄生虫的异常部位,主要在消化道,但也见于皮肤和肺部。86%的病例为亲内脏婴儿利什曼原虫酶株MON-1。从4例患者中分离出亲皮肤酶株MON-24、MON-29、MON-33和一种先前未描述的酶株MON-183。对五价锑的反应率为50%,对两性霉素B为100%,但两组均出现临床复发。在流行地区,VL应被视为HIV感染患者可能的机会性感染。(摘要截于250字)